Next-Generation Pulmonary Condition Treatment System
Legal Citation
Summary of the Inventive Concept
A novel, high-penetration prodrug composition and system for treating pulmonary conditions, leveraging AI-driven modeling, wearable technology, and nanoparticle-based delivery to enhance therapeutic efficacy and minimize side effects.
Background and Problem Solved
The original patent disclosed high penetration prodrug compositions for treating pulmonary conditions. However, these compositions have limitations in terms of selective targeting, dosing regimens, and patient compliance. The new inventive concept addresses these limitations by integrating advanced technologies to create a more efficient and personalized treatment system.
Detailed Description of the Inventive Concept
The new system comprises a novel, orally-administered, high-penetration prodrug composition that selectively targets and modulates specific biological pathways. The composition is engineered to utilize an advanced, AI-driven, pharmacokinetic modeling system to optimize dosing regimens and personalize treatment plans. Additionally, the system incorporates a wearable, transdermal patch with a sensor-enabled, real-time monitoring system to track treatment efficacy and patient compliance. The pharmaceutical composition is delivered via a nanoparticle-based system, enabling targeted, cellular-level delivery of the prodrug.
Novelty and Inventive Step
The new claims introduce a paradigm shift in pulmonary condition treatment by integrating AI-driven modeling, wearable technology, and nanoparticle-based delivery. These advancements enable selective targeting, personalized treatment plans, and real-time monitoring, which are not present in the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include variations in the prodrug composition, such as different nanoparticle sizes or shapes, or alternative delivery methods, such as injectable or inhalable formulations. Additionally, the AI-driven modeling system could be adapted for use in other disease areas or treatment modalities.
Potential Commercial Applications and Market
The next-generation pulmonary condition treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and digital health. The system's ability to enhance therapeutic efficacy and minimize side effects could lead to improved patient outcomes and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions, drug delivery systems, and pulmonary treatment technologies, with expertise in prodrug formulations, pharmacokinetic modeling, and targeted drug delivery mechanisms
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or biomedical engineer with advanced degrees, experience in drug development, knowledge of prodrug design, nanoparticle delivery systems, and familiarity with AI-driven pharmacological modeling techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of AI-driven modeling, nanoparticle delivery, and wearable monitoring represents predictable extensions of existing pharmaceutical development strategies. The core prodrug composition remains substantially similar to the source patent, with incremental technological enhancements that would be considered routine optimization by those skilled in pharmaceutical engineering. The proposed variations represent logical combinations of known techniques in drug delivery and personalized medicine.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,545 |
|---|---|
| Title | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| Assignee(s) | Techfields Pharma Co., Ltd. |